Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Allison T. Rhoads, PharmD, BCOP
Advertisement
Articles by Allison T. Rhoads, PharmD, BCOP
Asundexian was granted FDA Fast Track Designation based on a phase 2 study evaluating its safety and efficacy combined with antiplatelet therapy in patients following an acute, non-cardioembolic ischemic stroke.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments
3
Chronic Low Back Pain Treatments Must Be Weighed Against Risk, Cost, and Limited Benefit
4
Bringing Bispecific Therapy Into the Outpatient Community Oncology Setting
5